[Informe de investigación] Se espera que el tamaño del mercado de teranósticos radiofármacos crezca de 1.814,58 millones de dólares en 2022 a 3.441,97 millones de dólares en 2028; se estima que registrará una tasa compuesta anual del 11,3 % entre 2022 y 2028.
El mercado de teranósticos radiofarmacéuticos está segmentado según el tipo de producto, el radioisótopo, la fuente, la aplicación, la indicación, el usuario final y la geografía. El informe ofrece información y un análisis en profundidad del mercado, enfatizando parámetros como la dinámica, las tendencias y las oportunidades que prevalecen en el mercado de teranósticos radiofarmacéuticos. También proporciona el análisis del panorama competitivo de los principales actores del mercado global de teranósticos radiofarmacéuticos.
Perspectivas del mercado
La creciente aplicación en el tratamiento de trastornos cardiovasculares impulsa el crecimiento del mercado global de teranósticos radiofarmacéuticos
Las enfermedades cardiovasculares (ECV) se encuentran entre las enfermedades crónicas más prevalentes del siglo XXI, con una alta tasa de mortalidad. Debido a su estilo de vida sedentario, las ECV son la principal causa de mortalidad y morbilidad en los países desarrollados. Además, la obesidad, la diabetes y las enfermedades relacionadas se asocian con enfermedades cardiovasculares y se están volviendo comórbidas. Además, una complicación como la obstrucción de las arterias coronarias es una de las principales causas de muerte en adultos, resultando en una placa de trombos en la íntima de la pared arterial, principalmente en la arteria carótida. Según datos del Centro Nacional de Biotecnología, alrededor de 17,7 millones de personas murieron en todo el mundo en 2015 debido a enfermedades cardiovasculares. En este sentido, se estima que la mortalidad por enfermedades cardiovasculares podría aumentar a 22 millones en 2030. Las aplicaciones terapéuticas en enfermedades cardiovasculares incluyen la nanomedicina en angina de pecho, miocarditis, infarto de miocardio, enfermedad pericárdica, trombosis, aterosclerosis, hiperlipidemia, hipertensión, arteria pulmonar. hipertensión y accidente cerebrovascular. Las nanomedicinas teranósticas pueden prolongar la circulación sistémica, evadir los sistemas de defensa del huésped y administrar agentes teranósticos al sitio objetivo para obtener imágenes y terapia a nivel celular y molecular.
Información estratégica
Según el Según el informe de 2022 de los Centros para el Control y la Prevención de Enfermedades (CDC), las enfermedades cardíacas son una de las principales causas de muerte entre hombres y mujeres en los EE. UU. Las enfermedades cardíacas fueron la causa de ~697.000 muertes, es decir, 1 de cada 5 muertes, en los EE. UU. en 2020. Un informe del Instituto Nacional de Salud (NIH) afirma que las nanopartículas teranósticas han ganado una atención significativa en el campo médico, ya que las técnicas ayudan a superar complejidades y complicaciones fisiopatológicas asociadas con las ECV. Las imágenes cardiovasculares de pacientes con aterosclerosis proporcionan evidencia fisiopatológica que puede ayudar a tratar las ECV. Además, las nanopartículas teranósticas se pueden combinar con una variedad de técnicas de imagen, como la resonancia magnética (MRI), la tomografía por emisión de positrones (PET) y la tomografía computarizada (CT). Hasta ahora se han realizado varios estudios de investigación clínica en laboratorios clínicos. Se ha construido un complejo terapéutico tres en uno, combinando una sonda fotoacústica polimérica con nanopartículas-PLCDP@PMH. Las evaluaciones clínicas in vivo revelan que PLCDP@PMH proporciona ventajas lucrativas para el enfoque teranóstico para la detección de aterosclerosis en etapa temprana en pacientes.
Información basada en el tipo de producto
Basado en el tipo de producto , el mercado de teranósticos radiofármacos se segmenta en trazadores de tomografía por emisión de positrones (PET), emisores beta y emisores alfa. En 2022, el segmento de trazadores de tomografía por emisión de positrones (PET) tuvo la mayor participación de mercado en el mercado mundial de teranósticos radiofarmacéuticos y se prevé que registre la CAGR más alta durante el período de pronóstico.
Mercado de teranósticos radiofarmacéuticos, por tipo de producto: 2022-2028
Información basada en radioisótopos
Basado en radioisótopos, el mercado de teranósticos radiofarmacéuticos se divide en lutecio (Lu) 177, galio-68, yodo-131, yodo-123, Tecnecio-99, Itrio-90 (Y-90), Cobre (Cu) 64, 18F, Cobre (Cu) 67 y otros. En 2022, el segmento de lutecio (Lu) 177 tuvo la mayor cuota de mercado del mercado mundial de teranósticos radiofarmacéuticos y se prevé que registre la CAGR más alta durante el período de pronóstico.
Información basada en fuentes
< p>Según la fuente, el mercado de teranósticos radiofarmacéuticos se divide en ciclotrones y reactores nucleares. El segmento de ciclotrones tuvo una mayor participación de mercado en 2022 y se espera que registre una CAGR más alta durante el período de pronóstico.Información basada en aplicaciones
Según la aplicación, El mercado de teranósticos radiofármacos se divide en terapéutico dirigido (Rx) y diagnóstico complementario (CDx). En 2022, el segmento terapéutico dirigido (Rx) tuvo una mayor participación de mercado y se prevé que registre una CAGR más alta durante el período de pronóstico.
Información basada en indicaciones
Según la indicación, el mercado de teranósticos radiofarmacéuticos se segmenta en oncología, neurología, cardiología y otros. El segmento de oncología tuvo la mayor participación del mercado en 2022 y se prevé que registre la CAGR más alta durante el período de pronóstico.
Información basada en el usuario final
Basado en el usuario final , el mercado de teranósticos radiofarmacéuticos se segmenta en hospitales, centros de diagnóstico por imágenes, institutos académicos y de investigación, y otros. El segmento de hospitales tuvo la mayor participación de mercado en 2022. Sin embargo, se prevé que el segmento de institutos académicos y de investigación registre la CAGR más alta durante el período de pronóstico. Los hospitales emplean sistemas tecnológicamente avanzados para tratar aneurismas cardíacos, aneurismas neurológicos, tumores oncológicos y otras afecciones similares. La creciente prevalencia de diversas enfermedades y un número cada vez mayor de hospitales contribuyen al crecimiento del segmento de mercado de hospitales.
Los actores del mercado de teranósticos radiofarmacéuticos adoptan estrategias orgánicas, como el lanzamiento y la expansión de productos, para ampliar su huella y cartera de productos y satisfacer las crecientes demandas. Las estrategias de crecimiento inorgánico observadas en el mercado son asociaciones y colaboraciones. Estas estrategias de crecimiento han permitido a los actores del mercado expandir sus negocios y mejorar su presencia geográfica. Además, las adquisiciones, asociaciones y otras estrategias de crecimiento les ayudan a fortalecer su base de clientes.
- En octubre de 2022, Telix recibió la aprobación de Health Canada para su Illuccix, un Kit para la preparación de inyección de gozetotida de galio (68Ga). El producto se puede utilizar para estadificar y reestadificar el cáncer de próstata de riesgo intermedio y alto y para localizar tejido tumoral en el cáncer de próstata recurrente. Illuccix fue el primer agente de imágenes PET con PSMA que obtuvo la aprobación regulatoria en Canadá. Health Canada fue el tercer organismo regulador a nivel mundial en aprobar Illuccix, que está disponible comercialmente en Australia y EE. UU.
- En diciembre de 2021, GE Healthcare y Minerva Imaging firmaron una asociación estratégica para acelerar el lanzamiento comercial de medicamentos dirigidos. ;terapias con radionúclidos (teranósticos). La terapia con radionúclidos es una forma de medicina de precisión en la que se administra una sustancia radiactiva a través del torrente sanguíneo para atacar las células cancerosas e irradiarlas específicamente. Esto ayuda a reducir los posibles efectos secundarios en comparación con las terapias tradicionales contra el cáncer.
Perfiles de la empresa - Mercado de teranósticos radiofarmacéuticos
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications SA
- Jubilant Radiopharma
- Teragnóstico
- NuView Life Sciences
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. Nuclear medicine imaging generally utilizes radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics’. In theranostics, radiopharmaceuticals are used for therapeutic and diagnostic purposes by targeting one specific tumor receptor.
Key factors that are driving the growth of this market are rising incidence of cancer and the growing application in the treatment of cardiovascular disorders are expected to boost the market growth for the radiopharmaceutical theranostics over the years.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 11.3%.
The positron emission tomography (PET) tracers segment held the largest share of the market in the global radiopharmaceutical theranostics market and held the largest market share of 44.76% in 2022.
The Lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 24.34% in 2022.
The cyclotrons segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 60.42% in 2022.
Answer: - The targeted therapeutic [Rx] segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 63.28% in 2022.
The oncology segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 62.18% in 2022.
The hospitals segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 36.28% in 2022.
The radiopharmaceutical theranostics market majorly consists of the players such Bayer AG, GE HealthCare Technologies Inc, Curium, Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc, Advanced Accelerator Applications S.A.; Jubilant Radiopharma, Theragnostics, and NuView Life Sciences amongst others.
The List of Companies - Radiopharmaceutical Theranostics Market
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications S.A.
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)